Imatinib mesylate (Gleevec®) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity

European Journal of Pharmacology

Volumn 551, Issue 1-3, 2006, Pages 27-33

  El Hajj Dib, Iman ^a   Gallet, Marlène ^a   Mentaverri, Romuald ^a   Sévenet, Nicolas ^a   Brazier, Michel ^a   Kamel, Said ^a  

^a INSERM   (France)

Author keywords

Apoptosis; Bone resorption; Imatinib; Macrophage colony stimulating factor; Osteoclasts

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE INHIBITOR; COLONY STIMULATING FACTOR 1; IMATINIB; INTERLEUKIN 1ALPHA; OSTEOCLAST DIFFERENTIATION FACTOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL ACTIVITY; CELL DEATH; CELL STIMULATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; IN VITRO STUDY; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RABBIT;

AMINO ACID CHLOROMETHYL KETONES; ANIMALS; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; BONE RESORPTION; CASPASES; CELL SURVIVAL; CELLS, CULTURED; CYSTEINE PROTEINASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; INTERLEUKIN-1ALPHA; MACROPHAGE COLONY-STIMULATING FACTOR; OSTEOCLASTS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RABBITS; RANK LIGAND; TIME FACTORS;

EID: 33750456241     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.09.007     Document Type: Article

References (42)

1. Akiyama T., Bouillet P., Miyazaki T., Kadono Y., Chikuda H., Chung U.I., Fukuda A., Hikita A., Seto H., Okada T., Inaba T., Sanjay A., Baron R., Kawaguchi H., Oda H., Nakamura K., Strasser A., and Tanaka S. Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim. EMBO J. 22 (2003) 6653-6664
2. Berman E., Nicolaides M., Maki R.G., Fleisher M., Chanel S., Scheu K., Wilson B.A., Heller G., and Sauter N.P. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N. Engl. J. Med. 354 (2006) 2006-2013
3. Buchdunger E., Cioffi C.L., Law N., Stover D., Ohno-Jones S., Druker B.J., and Lydon N.B. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295 (2000) 139-145
4. Carroll M., Ohno-Jones S., Tamura S., Buchdunger E., Zimmermann J., Lydon N.B., Gilliland D.G., and Druker B.J. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90 (1997) 4947-4952
5. Cenci S., Weitzmann M.N., Gentile M.A., Aisa M.C., and Pacifici R. M-CSF neutralization and egr-1 deficiency prevent ovariectomy-induced bone loss. J. Clin. Invest. 105 (2000) 1279-1287
6. Conway J.G., McDonald B., Parham J., Keith B., Rusnak D.W., Shaw E., Jansen M., Lin P., Payne A., Crosby R.M., Johnson J.H., Frick L., Lin M.H., Depee S., Tadepalli S., Votta B., James I., Fuller K., Chambers T.J., Kull F.C., Chamberlain S.D., and Hutchins J.T. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 16078-16083
7. Dan S., Naito M., and Tsuruo T. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CGP 57148. Cell Death Differ. 5 (1998) 710-715
8. Dewar A.L., Cambareri A.C., Zannettino A.C., Miller B.L., Doherty K.V., Hughes T.P., and Lyons A.B. Macrophage colony-stimulating factor receptor c-FMS is a novel target of imatinib. Blood 105 (2005) 3127-3132
9. Dewar A.L., Doherty K.V., Hughes T.P., and Lyons A.B. Imatinib inhibits the functional capacity of cultured human monocytes. Immunol. Cell Biol. 83 (2005) 48-56
10. Dewar A.L., Farrugia A.N., Condina M.R., To L.B., Hughes T.P., Vernon-Roberts B., and Zannettino A.C. Imatinib as a potential anti-resorptive therapy for bone disease. Blood (2006) 4334-4337
11. Felix R., Cecchini M.G., Hofstetter W., Elford P.R., Stutzer A., and Fleisch H. Impairment of macrophage colony-stimulating factor production and lack of resident bone marrow macrophages in the osteopetrotic op/op mouse. J. Bone Miner. Res. 5 (1990) 781-789
12. Frith J.C., Monkkonen J., Auriola S., Monkkonen H., and Rogers M.J. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum. 44 (2001) 2201-2210
13. Fuller K., Owens J.M., Jagger C.J., Wilson A., Moss R., and Chambers T.J. Macrophage colony-stimulating factor stimulates survival and chemotactic behavior in isolated osteoclasts. J. Exp. Med. 178 (1993) 1733-1744
14. Gallet M., Sevenet N., Dupont C., Brazier M., and Kamel S. Breast cancer cell line MDA-MB 231 exerts a potent and direct anti-apoptotic effect on mature osteoclasts. Biochem. Biophys. Res. Commun. 319 (2004) 690-696
15. Glantschnig H., Fisher J.E., Wesolowski G., Rodan G.A., and Reszka A.A. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ. 10 (2003) 1165-1177
16. Hofstetter W., Wetterwald A., Cecchini M.C., Felix R., Fleisch H., and Mueller C. Detection of transcripts for the receptor for macrophage colony-stimulating factor, c-FMS, in murine osteoclasts. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 9637-9641
17. Hughes D.E., and Boyce B.F. Apoptosis in bone physiology and disease. Mol. Pathol. 50 (1997) 132-137
18. Hughes D.E., Wright K.R., Uy H.L., Sasaki A., Yoneda T., Roodman G.D., Mundy G.R., and Boyce B.F. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. 10 (1995) 1478-1487
19. Jimi E., Shuto T., and Koga T. Macrophage colony-stimulating factor and interleukin-1 alpha maintain the survival of osteoclast-like cells. Endocrinology 136 (1995) 808-811
20. Kameda T., Ishikawa H., and Tsutsui T. Detection and characterization of apoptosis in osteoclasts in vitro. Biochem. Biophys. Res. Commun. 207 (1995) 753-760
21. Kameda T., Mano H., Yuasa T., Mori Y., Miyazawa K., Shiokawa M., Nakamaru Y., Hiroi E., Hiura K., Kameda A., Yang N.N., Hakeda Y., and Kumegawa M. Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J. Exp. Med. 186 (1997) 489-495
22. Kaplan C., and Finnegan A. Osteoclasts, pro-inflammatory cytokines, RANK-L and bone remodeling in rheumatoid arthritis. Front. Biosci. 8 (2003) 1018-1029
23. Kitaura H., Zhou P., Kim, Novack D.V., Ross F.P., and Teitelbaum S.L. M-CSF mediates TNF-induced inflammatory osteolysis. J. Clin. Invest. 115 (2005) 3418-3427
24. Mancino A.T., Klimberg V.S., Yamamoto M., Manolagas S.C., and Abe E. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J. Surg. Res. 100 (2001) 18-24
25. Manolagas S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21 (2000) 115-137
26. Murray L.J., Abrams T.J., Long K.R., Ngai T.J., Olson L.M., Hong W., Keast P.K., Brassard J.A., O'Farrell A.M., Cherrington J.M., and Pryer N.K. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin. Exp. Metastasis 20 (2003) 757-766
27. Oetzel C., Jonuleit T., Gotz A., van der Kuip H., Michels H., Duyster J., Hallek M., and Aulitzky W.E. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X. Clin. Cancer Res. 6 (2000) 1958-1968
28. Okada M., Adachi S., Imai T., Watanabe K., Toyokuni S.Y., Ueno M., Zervos A.S., Kroemer G., and Nakahata T. A novel mechanism for imatinib mesylate-induced cell death of BCR-ABL-positive human leukemic cells: caspase-independent, necrosis-like programmed cell death mediated by serine protease activity. Blood 103 (2004) 2299-2307
29. Parfitt A.M., Mundy G.R., Roodman G.D., Hughes D.E., and Boyce B.F. A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J. Bone Miner. Res. 11 (1996) 150-159
30. Peng B., Hayes M., Resta D., Racine-Poon A., Druker B.J., Talpaz M., Sawyers C.L., Rosamilia M., Ford J., Lloyd P., and Capdeville R. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J. Clin. Oncol. 22 (2004) 935-942
31. Reszka A.A., Halasy-Nagy J.M., Masarachia P.J., and Rodan G.A. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J. Biol. Chem. 274 (1999) 34967-34973
32. Rodan G.A., and Martin T.J. Therapeutic approaches to bone diseases. Science 289 (2000) 1508-1514
33. Roodman G.D. Biology of osteoclast activation in cancer. J. Clin. Oncol. 19 (2001) 3562-3571
34. Sugatani T., and Hruska K.A. Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. J. Biol. Chem. 280 (2005) 3583-3589
35. Tanaka S., Takahashi N., Udagawa N., Tamura T., Akatsu T., Stanley E.R., Kurokawa T., and Suda T. Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J. Clin. Invest. 91 (1993) 257-263
36. Tanaka S., Nakamura K., Takahasi N., and Suda T. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol. Rev. 208 (2005) 30-49
37. Taylor J.R., Brownlow N., Domin J., and Dibb N.J. FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. Oncogene 25 (2006) 147-151
38. Teitelbaum S.L. Bone resorption by osteoclasts. Science 289 (2000) 1504-1508
39. Tezuka K., Sato T., Kamioka H., Nijweide P.J., Tanaka K., Matsuo T., Ohta M., Kurihara N., Hakeda Y., and Kumegawa M. Identification of osteopontin in isolated rabbit osteoclasts. Biochem. Biophys. Res. Commun. 186 (1992) 911-917
40. Vaananen K. Mechanism of osteoclast mediated bone resorption-rationale for the design of new therapeutics. Adv. Drug Deliv. Rev. 57 (2005) 959-971
41. Xing L., and Boyce B.F. Regulation of apoptosis in osteoclasts and osteoblastic cells. Biochem. Biophys. Res. Commun. 328 (2005) 709-720
42. Yang S., Zhang Y., Rodriguiz R.M., Ries W.L., and Key Jr. L.L. Functions of the M-CSF receptor on osteoclasts. Bone 18 (1996) 355-360